Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc.verified

IKT

Price:

$3.02

Market Cap:

$202.92M

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in ...[Read more]

Industry

Biotechnology

IPO Date

2020-12-23

Stock Exchange

NASDAQ

Ticker

IKT

The Dividend Yield as of December 2024 (TTM) for Inhibikase Therapeutics, Inc. (IKT) is 0%

According to Inhibikase Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Dividend Yield is 0%. This represents a change of 0% compared to the average of 0% of the last 4 quarters.

Inhibikase Therapeutics, Inc. (IKT) Historical Dividend Yield (quarterly & annually)

How has IKT Dividend Yield performed in the past?

The mean historical Dividend Yield of Inhibikase Therapeutics, Inc. over the last ten years is 0%. The current 0% Dividend Yield has changed 0% with respect to the historical average. Over the past ten years (40 quarters), IKT's Dividend Yield was at its highest in in the March 2017 quarter at 0%. The Dividend Yield was at its lowest in in the March 2017 quarter at 0%.

Quarterly (TTM)
Annual

Average

0%

Median

0%

Minimum

0%

Maximum

0%

Inhibikase Therapeutics, Inc. (IKT) Dividend Yield by Quarter and Year

Discovering the peaks and valleys of Inhibikase Therapeutics, Inc. Dividend Yield, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 0%

Maximum Annual Dividend Yield = 0%

Minimum Annual Increase = 0%

Minimum Annual Dividend Yield = 0%

Quarterly (TTM)
Annual
YearDividend YieldChange
20230%0%
20220%0%
20210%0%
20200%0%
20190%0%
20180%0%
20170%0%

Inhibikase Therapeutics, Inc. (IKT) Average Dividend Yield

How has IKT Dividend Yield performed in the past?

The current Dividend Yield of Inhibikase Therapeutics, Inc. (IKT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

0%

5-year avg

0%

10-year avg

0%

Inhibikase Therapeutics, Inc. (IKT) Dividend Yield vs. Peers

How is IKT’s Dividend Yield compared to its peers?

Inhibikase Therapeutics, Inc.’s Dividend Yield is less than DiaMedica Therapeutics Inc. (0%), less than Milestone Pharmaceuticals Inc. (0%), less than Seres Therapeutics, Inc. (0%), less than Oncolytics Biotech Inc. (0%), less than scPharmaceuticals Inc. (0%), less than aTyr Pharma, Inc. (0%), less than Sio Gene Therapies Inc. (0%), less than Kaleido Biosciences, Inc. (91.00%), less than Tempest Therapeutics, Inc. (0%), less than AN2 Therapeutics, Inc. (0%), less than Miromatrix Medical Inc. (0%), less than PMV Pharmaceuticals, Inc. (0%), less than Anebulo Pharmaceuticals, Inc. (0%), less than Nutriband Inc. (0%), less than Quoin Pharmaceuticals, Ltd. (0%), less than Longeveron Inc. (0%), less than RenovoRx, Inc. (0%), less than Virax Biolabs Group Limited (0%), less than null (0%),

Build a custom stock screener for Inhibikase Therapeutics, Inc. (IKT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Inhibikase Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Inhibikase Therapeutics, Inc. (IKT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Inhibikase Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Dividend Yield?

How can you use the Dividend Yield?

What is Inhibikase Therapeutics, Inc.'s Dividend Yield?

How is the Dividend Yield calculated for Inhibikase Therapeutics, Inc. (IKT)?

What is the highest Dividend Yield for Inhibikase Therapeutics, Inc. (IKT)?

What is the 3-year average Dividend Yield for Inhibikase Therapeutics, Inc. (IKT)?

What is the 5-year average Dividend Yield for Inhibikase Therapeutics, Inc. (IKT)?

How does the current Dividend Yield for Inhibikase Therapeutics, Inc. (IKT) compare to its historical average?